Idera Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.39 Insider Own0.50% Shs Outstand52.97M Perf Week5.32%
Market Cap22.91M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float40.85M Perf Month-19.59%
Income-20.70M PEG- EPS next Q- Inst Own6.80% Short Float1.35% Perf Quarter-10.18%
Sales- P/S- EPS this Y158.10% Inst Trans-3.48% Short Ratio5.20 Perf Half Y-25.37%
Book/sh0.40 P/B1.01 EPS next Y- ROA-63.50% Target Price- Perf Year-60.37%
Cash/sh- P/C- EPS next 5Y- ROE-75.70% 52W Range0.29 - 1.04 Perf YTD-29.09%
Dividend- P/FCF- EPS past 5Y22.90% ROI- 52W High-61.13% Beta1.42
Dividend %- Quick Ratio5.40 Sales past 5Y- Gross Margin- 52W Low37.02% ATR0.04
Employees13 Current Ratio5.40 Sales Q/Q- Oper. Margin- RSI (14)44.54 Volatility8.72% 9.74%
OptionableYes Debt/Eq0.00 EPS Q/Q33.90% Profit Margin- Rel Volume0.86 Prev Close0.39
ShortableYes LT Debt/Eq0.00 EarningsAug 09 AMC Payout- Avg Volume105.84K Price0.40
Recom3.00 SMA20-5.98% SMA50-8.94% SMA200-18.38% Volume90,949 Change2.69%
Mar-19-21Downgrade Wedbush Outperform → Neutral $8 → $1
Mar-19-21Downgrade JP Morgan Overweight → Neutral
Mar-19-21Downgrade JMP Securities Mkt Outperform → Mkt Perform
Mar-19-21Downgrade H.C. Wainwright Buy → Neutral
Mar-19-21Downgrade Barclays Overweight → Equal Weight $10 → $2
Sep-24-18Initiated Barclays Overweight $14
Aug-15-18Resumed JP Morgan Overweight $15
Nov-09-17Initiated H.C. Wainwright Buy $4
Apr-25-17Initiated Robert W. Baird Outperform $5
Mar-22-17Initiated JMP Securities Mkt Outperform
Feb-01-17Reiterated Wedbush Outperform $6
Jan-06-16Initiated Wedbush Outperform $6
Jun-15-15Initiated JP Morgan Overweight
Mar-03-14Initiated Cowen Outperform
Mar-24-10Upgrade Rodman & Renshaw Mkt Perform → Mkt Outperform $10
Nov-21-08Initiated Noble Financial Buy
Oct-27-08Upgrade Susquehanna Financial Negative → Neutral
Aug-06-08Downgrade Canaccord Adams Buy → Hold
May-07-08Downgrade Janney Mntgmy Scott Buy → Neutral
May-02-08Downgrade Susquehanna Financial Neutral → Negative $11
Sep-29-22 09:52AM
Sep-28-22 08:34PM
Aug-09-22 04:15PM
May-19-22 11:14AM
11:59AM Loading…
May-17-22 11:59AM
May-05-22 04:15PM
Mar-31-22 04:15PM
Dec-14-21 04:32PM
Nov-08-21 04:14PM
Aug-09-21 04:15PM
Jun-05-21 05:59AM
May-19-21 07:56AM
04:15PM Loading…
May-18-21 04:15PM
Apr-29-21 04:10PM
Mar-19-21 12:04PM
Mar-18-21 04:15PM
Mar-07-21 03:31AM
Mar-01-21 04:35PM
Feb-28-21 02:49AM
Feb-26-21 06:50AM
Jan-11-21 06:02AM
02:22AM Loading…
Dec-18-20 02:22AM
Dec-17-20 08:45AM
Dec-15-20 08:05AM
Dec-04-20 08:34AM
Nov-17-20 04:27PM
Nov-03-20 07:10AM
Oct-29-20 04:36PM
Sep-28-20 08:45AM
Sep-15-20 07:18AM
Sep-10-20 10:13AM
Aug-04-20 04:10PM
Jul-15-20 08:05AM
Jun-21-20 11:13PM
Jun-02-20 08:15AM
May-01-20 08:00AM
Apr-30-20 04:35PM
Apr-23-20 07:30AM
Apr-21-20 07:30AM
Apr-10-20 01:49PM
Apr-07-20 04:05PM
Mar-12-20 07:30AM
Mar-06-20 11:14AM
Mar-05-20 07:00AM
Jan-14-20 07:00AM
Dec-24-19 12:05PM
Dec-23-19 09:15AM
Dec-16-19 04:39PM
Nov-19-19 09:40AM
Nov-06-19 04:01PM
Nov-01-19 10:03AM
Oct-25-19 10:46AM
Oct-21-19 07:00AM
Sep-30-19 07:30AM
Sep-10-19 09:33AM
Sep-04-19 07:00AM
Aug-30-19 12:00PM
Aug-17-19 04:20AM
Aug-08-19 10:15AM
Aug-06-19 04:00PM
Jul-25-19 10:33AM
Jul-23-19 07:30AM
Jul-10-19 01:46PM
Jun-18-19 04:00PM
May-10-19 09:35AM
May-02-19 08:55PM
May-01-19 10:32AM
Apr-29-19 08:34AM
Apr-10-19 07:00AM
Apr-02-19 07:00AM
Mar-14-19 11:21AM
Mar-07-19 01:55PM
Mar-06-19 04:30PM
Feb-27-19 07:00AM
Jan-23-19 12:55PM
Jan-18-19 01:08PM
Jan-04-19 07:30AM
Dec-18-18 04:05PM
Dec-17-18 07:00AM
Dec-14-18 07:00AM
Dec-12-18 04:01PM
Dec-11-18 07:20AM
Dec-08-18 10:02AM
Nov-27-18 01:01PM
Nov-06-18 06:35PM
Oct-19-18 06:00AM
Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kirby John J.CHIEF FINANCIAL OFFICERDec 17Buy0.6110,0006,15037,632Dec 21 04:16 PM